Equities research analysts expect Rocket Pharmaceuticals Inc (NASDAQ:RCKT) to post ($0.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Rocket Pharmaceuticals’ earnings, with estimates ranging from ($0.75) to ($0.40). Rocket Pharmaceuticals reported earnings per share of ($0.40) in the same quarter last year, which would indicate a negative year-over-year growth rate of 25%. The firm is expected to report its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Rocket Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.43) to ($1.55). For the next financial year, analysts anticipate that the company will post earnings of ($2.44) per share, with EPS estimates ranging from ($3.55) to ($1.89). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Rocket Pharmaceuticals.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.10.

RCKT has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Rocket Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, August 13th. ValuEngine upgraded shares of Rocket Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Oppenheimer cut their price objective on shares of Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Finally, William Blair reiterated a “buy” rating on shares of Rocket Pharmaceuticals in a report on Tuesday. Ten analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $28.00.

Rocket Pharmaceuticals stock traded up $0.52 during trading hours on Friday, reaching $14.09. 245,975 shares of the stock were exchanged, compared to its average volume of 302,368. The stock has a market cap of $679.70 million, a P/E ratio of -7.46 and a beta of 2.71. The company has a debt-to-equity ratio of 0.18, a quick ratio of 17.48 and a current ratio of 17.48. Rocket Pharmaceuticals has a 52-week low of $10.75 and a 52-week high of $25.96. The firm’s 50 day moving average is $11.68 and its 200 day moving average is $15.34.

Institutional investors and hedge funds have recently made changes to their positions in the company. Spark Investment Management LLC purchased a new position in shares of Rocket Pharmaceuticals in the 1st quarter valued at about $564,000. Zeke Capital Advisors LLC purchased a new position in shares of Rocket Pharmaceuticals in the 2nd quarter valued at about $153,000. Group One Trading L.P. increased its holdings in shares of Rocket Pharmaceuticals by 103.6% in the 1st quarter. Group One Trading L.P. now owns 1,999 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,017 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Rocket Pharmaceuticals in the 1st quarter valued at about $2,560,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Rocket Pharmaceuticals in the 1st quarter valued at about $3,073,000. Institutional investors and hedge funds own 97.15% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Further Reading: Are sell-side analysts objective?

Get a free copy of the Zacks research report on Rocket Pharmaceuticals (RCKT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.